Rezolute is no longer the clean congenital hyperinsulinism Phase 3 story the market priced last year. The sunRIZE trial missed its primary endpoint in December, and the equity now lives on whether regulators accept continuous-glucose-monitor analyses and open-label extension evidence as enough to keep that indication alive. A separate tumor hyperinsulinism study posted a clean interim signal that now carries more of the commercial argument than the congenital program. The investment debate is whether that salvage pair is worth a mid-hundreds-of-millions enterprise value, or whether the December miss already defined the residual claim as cash plus a small open-label option.
The March quarter showed the cost of that reset. Cash and marketable securities stood near $120 million after nine months of burn, with no product revenue and almost no funded debt. Operating cash use ran about $51 million over those nine months, and management cut twenty-nine roles after the miss to slow the drain. The Jefferies at-the-market facility was terminated unused in October, so the next raise, if one arrives, is a discrete event rather than a drip. Shares last traded at $3.84, implying roughly $370 million of equity value on the basic count and a far thinner enterprise value after cash. The fifty-two-week range from $1.07 to the pre-miss high tells the same story as the science: the market already priced collapse, then priced a partial revival.
What remains unresolved is binary and close. The agency still has the June data package under review, and the company has not said whether a marketing application is even in play. The upLIFT tumor study is halfway enrolled, with six of the first eight participants already off intravenous glucose, and management still targets a full topline before year-end. Does the Food and Drug Administration treat continuous-monitor evidence as a path, or does it send congenital hyperinsulinism back to a new controlled trial while tumor data has to carry the entire franchise?